Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Xia ^a   Xu, Tian Ying ^a   Liu, Xin Zhu ^a   Zhang, Sai Long ^a   Wang, Pei ^a   Li, Zhi Yong ^a   Guan, Yun Feng ^a   Wang, Shu Na ^a   Dong, Guo Qiang ^a   Zhuo, Shu ^b,c   Le, Ying Ying ^b,c   Sheng, Chun Quan ^a   Miao, Chao Yu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYTOKINE; ENZYME INHIBITOR; F671-0003; FLUORESCENT DYE; M049-0244; MOLECULAR LIBRARY; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, MOUSE; QUINOXALINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; HEP-G2 CELL LINE; HUMAN; MOLECULAR LIBRARY; MOUSE; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CYTOKINES; DRUG DISCOVERY; ENZYME INHIBITORS; FLUORESCENT DYES; HEP G2 CELLS; HUMANS; MICE; MICE, TRANSGENIC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; QUINOXALINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84938544861     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12657     Document Type: Article

References (31)

1. Garten, A., Petzold, S., Korner, A., Imai, S. & Kiess, W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130-138 (2009).
2. Dahl, T. B., Holm, S., Aukrust, P. & Halvorsen, B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr. 32, 229-243 (2012).
3. Wang, P., Vanhoutte, P. M. & Miao, C. Y. Visfatin and cardio-cerebro-vascular disease. J. Cardiovasc. Pharmacol. 59, 1-9 (2012).
4. Buldak, R. J. et al. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol. Rep. 29, 771-778 (2013).
5. Miao, C. Y. Introduction: Adipokines and cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 38, 860-863 (2011).
6. Galli, U. et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J. Med. Chem. 56, 6279-6296 (2013).
7. Ravaud, A. et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur. J. Cancer 41, 702-707 (2005).
8. Holen, K., Saltz, L. B., Hollywood, E., Burk, K. & Hanauske, A. R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26, 45-51 (2008).
9. von Heideman, A., Berglund, A., Larsson, R. & Nygren, P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65, 1165-1172 (2010).
10. Matheny, C. J. et al. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chem. Biol. 20, 1352-1363 (2013).
11. Zheng, X. et al. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. J. Med. Chem. 56, 4921-4937 (2013).
12. Christensen, M. K. et al. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. J. Med. Chem. 56, 9071-9088 (2013).
13. Giannetti, A. M. et al. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). J. Med. Chem. 57, 770-792 (2014).
14. Zhang, R. Y. et al. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. Anal. Biochem. 412, 18-25 (2011).
15. Xu, T. Y. et al. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. Sci. Rep. 5, 10043 (2015).
16. De La Fuente, J. R., Canete, A., Zanocco, A. L., Saitz, C. & Jullian, C. Formal hydride transfer mechanism for photoreduction of 3-phenylquinoxalin-2-ones by amines. Association Of 3-phenylquinoxalin-2-one with aliphatic amines. J. Org. Chem. 65, 7949-7958 (2000).
17. Wang, P. et al. Intracellular NAMPT-NAD+ -SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors. Cardiovasc. Res. 104, 477-488 (2014).
18. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
19. Schuster, S. et al. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. Biochem. Biophys. Res. Commun. 458, 334-340 (2015).
20. Hasmann, M. & Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436-7442 (2003).
21. Sampath, D., Zabka, T. S., Misner, D. L., O'Brien, T. & Dragovich, P. S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol. Ther. 151, 16-31 (2015).
22. Morris-Blanco, K. C., Cohan, C. H., Neumann, J. T., Sick, T. J. & Perez-Pinzon, M. A. Protein kinase C epsilon regulates mitochondrial pools of Nampt and NAD following resveratrol and ischemic preconditioning in the rat cortex. J. Cereb. Blood Flow Metab. 34, 1024-1032 (2014).
23. Yang, H. et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130, 1095-1107 (2007).
24. Pittelli, M. et al. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J. Biol. Chem. 285, 34106-34114 (2010).
25. Rowlands, M. G. et al. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 327, 176-183 (2004).
26. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen 4, 67-73 (1999).
27. Wang, P. et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc. Res. 81, 370-380 (2009).
28. Matsumura, H. & Miyachi, S. Cycling Assay for Nicotinamide Adenine Dinucleotides. Methods In Enzymology 69, 465-470 (1980).
29. Wang, P. et al. Loss of AMP-activated protein kinase-alpha2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. Diabetes 61, 1051-1061 (2012).
30. Klaunig, J. E. et al. Mouse liver cell culture. I. Hepatocyte isolation. In Vitro 17, 913-925 (1981).
31. Klaunig, J. E., Goldblatt, P. J., Hinton, D. E., Lipsky, M. M. & Trump, B. F. Mouse liver cell culture. II. Primary culture. In Vitro 17, 926-934 (1981).